BioAffinity Technologies Inc. (BIAF)
NASDAQ (CM) NASDAQ (CM) Primary 
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung diagnostic, even as total revenue declined following a strategic shift away from lower-margin lab services. Here's what investors need to know.
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead?
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
